| Title: | Mechanism of action, potency and efficacy : considerations for cell therapies |
|---|
| Authors: | ID Simon Jr., Carl G. (Author)
ID Bozenhardt, Erich H. (Author)
ID Celluzzi, Christina M. (Author)
ID Dobnik, David (Author)
ID Grant, Melanie L. (Author)
ID Lakshmipathy, Uma (Author)
ID Nebel, Thiana (Author) |
|---|
| Files: |  URL - Source URL, visit https://doi.org/10.1186/s12967-024-05179-7
 PDF - Presentation file, download (4,26 MB)
MD5: 98DD6E0119EEFC3B0509163C71948613
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  NIB - National Institute of Biology
|
|---|
| Abstract: | One of the most challenging aspects of developing advanced cell therapy products (CTPs) is defining the mechanism of action (MOA), potency and efficacy of the product. This perspective examines these concepts and presents helpful ways to think about them through the lens of metrology. A logical framework for thinking about MOA, potency and efficacy is presented that is consistent with the existing regulatory guidelines, but also accommodates what has been learned from the 27 US FDA-approved CTPs. Available information regarding MOA, potency and efficacy for the 27 FDA-approved CTPs is reviewed to provide background and perspective. Potency process and efficacy process charts are introduced to clarify and illustrate the relationships between six key concepts: MOA, potency, potency test, efficacy, efficacy endpoint and efficacy endpoint test. Careful consideration of the meaning of these terms makes it easier to discuss the challenges of correlating potency test results with clinical outcomes and to understand how the relationships between the concepts can be misunderstood during development and clinical trials. Examples of how a product can be “potent but not efficacious” or “not potent but efficacious” are presented. Two example applications of the framework compare how MOA is assessed in cell cultures, animal models and human clinical trials and reveals the challenge of establishing MOA in humans. Lastly, important considerations for the development of potency tests for a CTP are discussed. These perspectives can help product developers set appropriate expectations for understanding a product’s MOA and potency, avoid unrealistic assumptions and improve communication among team members during the development of CTPs. |
|---|
| Keywords: | cell therapy product, efficacy endpoint test, mechanism of action, potency test, metrology |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Publication date: | 02.05.2024 |
|---|
| Year of publishing: | 2024 |
|---|
| Number of pages: | str. [1]-17 |
|---|
| Numbering: | Vol. 22, art. no. ǂ416 |
|---|
| PID: | 20.500.12556/DiRROS-19009  |
|---|
| UDC: | 576 |
|---|
| ISSN on article: | 1479-5876 |
|---|
| DOI: | 10.1186/s12967-024-05179-7 |
|---|
| COBISS.SI-ID: | 196774659 |
|---|
| Note: | Soavtorji: Erich H. Bozenhardt, Christina M. Celluzzi, David Dobnik, Melanie L. Grant, Uma Lakshmipathy, Thiana Nebel, Linda Peltier, Anthony Ratcliffe, James L. Sherley, Glyn N. Stacey, Rouzbeh R. Taghizadeh, Eddie H. P. Tan & Sandrine Vessillier;
Nasl. z nasl. zaslona;
Opis vira z dne 27. 5. 2024;
|
|---|
| Publication date in DiRROS: | 27.05.2024 |
|---|
| Views: | 121 |
|---|
| Downloads: | 122 |
|---|
| Metadata: |     |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
